Create the strongest possible appeal, the easy way From the right clinical studies to specific appeal precedents that apply to your unique circumstances, at Claimable we know how to fight and win forced switches like these
The criteria are: Adults with a BMI of 30 or higher Adults with a body mass index (BMI) of 27 or higher and a related condition, such as high blood pressure, type 2 diabetes, or abnormal cholesterol People with a history of cardiovascular disease, who have seen additional benefits for heart health with GLP-1 therapy Some GLP-1 drugs have been shown to slow disease progression in people with chronic kidney disease BMI is a good first checkpoint to see where you fall
Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and as anti-obesity medication for long-term weight management Medications Wegovy (GLP-1) Once-weekly semaglutide injection that has shown ~15.9% average weight loss in clinical trials
Semaglutide slows gastric emptying, which can in theory affect the absorption timing of oral medications
Intraduodenal administration of sucrose, sucralose, and the artificial sweetener PALSWEET each significantly increase lymph GLP-2 output compared to saline control (Sato et al., 2013)
Our program utilizes a variety of treatment modalities, including recommendations on nutrition, exercise, supplements, and medications to assist you in reaching your optimal weight
